TheWealthWeb

WhiteOak Capital Pharma and Healthcare Fund Direct Growth

WhiteOak Capital Mutual FundEquity Schemes - Sectoral FundDirect · GrowthRisk: Very High Risk

NAV ₹18.455 on 13 November 2026

AMFI name: WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth · Scheme code 152349 · ISIN INF03VN01886

1 year
+26.34%
Since launch, a year
+24.48%
NAV performance, last year

Returns

To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.

PeriodThis fundNIFTY HEALTHCARE INDEX TRICategory median
1M+10.36%+8.67%+8.37%
6M+18.15%+12.84%+10.20%
1Y+26.34%+38.92%+5.55%
3Y-+28.05%+16.88%
5Y--+15.07%

Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates.

Category median: the middle return among Direct plans (Growth option) in AMFI's “Equity Schemes - Sectoral Fund” category, up to 20 funds with clean data. Ranks are under “Rank among peers”.

Risk

From daily NAVs. Alpha, beta and capture are measured against NIFTY HEALTHCARE INDEX TRI.

Volatility
14.04%
Annualised, 1 year
Max drawdown
-15.39%
Worst fall from a peak, 3 years
Sharpe ratio
1.45
Return above the risk-free rate per unit of volatility, 1 year
Sortino ratio
1.67
Like Sharpe, counting only falls, 3 years
Alpha
+8.52%
Return a year beyond what beta explains, 3 years
Beta
0.55
1.00 moves in step with the benchmark, 3 years
Upside capture
63%
Share of the benchmark's rises captured, 3 years
Downside capture
93%
Share of the benchmark's falls taken (lower is better), 3 years

Rank among peers

Direct plans, Growth option, in AMFI's “Equity Schemes - Sectoral Fund” category. Each rank counts only the peers that have that figure.

Compare with Top Peers
3-Year Return Rank
-of 142
-
N/A
Q1
Q2
Q3
Q4
1-Year Return RankQ1
#7of 233
+26.34%
Ahead of 226 of the other 232
Q1
Q2
Q3
Q4
Sharpe (Risk-Adjusted)Q1
#5of 233
1.45
Ahead of 228 of the other 232
Q1
Q2
Q3
Q4
Highest 3-year returns in the categoryDirect plans · Growth option
RankScheme Name3Y Return1Y ReturnSharpeDirect TERAUM
#1
Nippon India Mutual Fund
+46.52%+60.64%1.071.06%₹1,100 Cr
#2
HDFC Mutual Fund
+33.64%+20.34%1.070.89%₹11,128 Cr
#3
HDFC Mutual Fund
+31.28%+31.60%1.761.03%₹3,128 Cr
#4
SBI Mutual Fund
+25.42%+26.07%1.470.76%₹5,565 Cr
#5
HDFC Mutual Fund
+24.77%+10.10%1.091.10%₹1,997 Cr
#6
Mirae Asset Mutual Fund
+24.42%+27.89%1.28-₹3,458 Cr
#7
UTI Mutual Fund
+23.89%+22.00%1.311.35%₹1,399 Cr
#8
ICICI Prudential Mutual Fund
+22.73%+10.29%0.952.08%₹3,926 Cr
#-
WhiteOak Capital Pharma and Healthcare FundCurrent Fund
WhiteOak Capital Mutual Fund
-+26.34%1.451.07%₹858 Cr

Costs and fund facts

Expense ratio (stated maximum)
Direct 1.07% · Regular 2.74%
Exit load
Nil
Fund size (all plans)
₹858 CrAverage, quarter to September 2026
Benchmark
NIFTY HEALTHCARE INDEX TRI
Allotment date
6 February 2024Scheme document
Type
An open ended equity scheme investing in Pharma and Healthcare sector.
AMFI scheme code
152349

Fund managers (5)

  • Ramesh Mantrisince 06-Feb-2024
  • Piyush Baranwalsince 06-Feb-2024
  • Dheeresh Pathaksince 06-Feb-2024
  • Ashish Agrawalsince 06-Jan-2025
  • Trupti Agrawalsince 20-May-2025

How each manager has done since taking over: fund manager scorecard.

Investment objective

To provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.

From the scheme summary document filed with AMFI.

SIP calculator

A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.

Monthly SIP Amount₹10,000
Investment Horizon5 Years
Simulating monthly 1st from 7 Feb 2024 to 13 Nov 2026
Total Invested34 mos
₹3,40,000
Units: 25,665.27
Current Portfolio Value
₹4,73,653
At latest recorded NAV
Total Profit
+₹1,33,653
+39.3% absolute return
SIP XIRR
25.09%
Annualised, money-weighted
Wealth CompositionProfit is 39% of total invested capital
Invested: ₹3,40,000Profit Generated: ₹1,33,653
Same SIP in the benchmark (NIFTY HEALTHCARE INDEX TRI)Same dates & amounts
Scheme SIP Valuation
₹4,73,653
25.1% XIRR
Benchmark SIP Valuation
₹5,56,767
25.8% XIRR
Fund minus benchmark
₹-83,114
Over 34 monthly installments
SIP instalments are bought on the first NAV date of each month; values use the latest NAV we hold. Past returns are not a guide to future returns.

About this fund

WhiteOak Capital Pharma and Healthcare Fund Direct Growth is a mutual fund scheme from WhiteOak Capital Mutual Fund, listed by AMFI under “Equity Schemes - Sectoral Fund”. This page covers the Direct plan with the Growth option. Its NAV was ₹18.455 on 13 November 2026. It returned 26.34% over 1 year, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY HEALTHCARE INDEX TRI, returned 38.92% over 1 year. Q-Score: 74 out of 100, rated only against funds in the same category. The fund house rates its risk as “Very High Risk” on the SEBI riskometer. Its average assets under management were ₹858 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 1.07% a year for the Direct plan. Managed by Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal and Trupti Agrawal. Its scheme summary document gives the allotment date as 6 February 2024.

Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.

Plans and options of this fund (2)

PlanOptionISINAMFI codeNAV
DirectThis pageGrowthINF03VN01886152349₹18.4613 Nov 2026
RegularGrowthINF03VN01878152348₹17.5913 Nov 2026